XSTO
ERMA
Market cap4mUSD
Oct 07, Last price
0.61SEK
1D
-5.28%
1Q
129.32%
Jan 2017
-93.07%
IPO
-91.90%
Name
Enorama Pharma AB
Chart & performance
P/E
—
P/S
16.61
EPS
—
Div yield, %
—
Shrs. gr., 5y
59.43%
Rev. gr., 5y
5.00%
Revenues
3m
-82.63%
Net income
-75m
L+71.53%
CFO
-59m
L+65.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.
Key people
Bengt Joensson
Acting Chief Executive Officer · since 2025
Daniel Schroder
Chief Executive Officer · since 2024
Claes Eliasson
Acting Chief Financial Officer · since 2025
Ara Abrahamian
Chairman of the Board · since 2025
Fredrik Olsson
Director · since 2023
Mats Ronngard
Director · since 2024
Tanu Tandan
Director · since 2024
Mikael Abom
Independent Director · since 2025
Headquarters & legal address
Strandvägen 7A
Stockholm, AB 114 51
SE
Stockholm, AB 114 51
SE
Address
Strandvagen 7A
Stockholm, AB 114 51
SE
Stockholm, AB 114 51
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||